Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Bryon D. Johnson PhD

Bryon D. Johnson PhD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


Publications

  • A serum-induced transcriptome and serum cytokine signature obtained at diagnosis correlates with the development of early pancreatic ductal adenocarcinoma metastasis. (Tsai S, McOlash L, Jia S, Zhang J, Simpson P, Kaldunski ML, Aldakkak M, Grewal J, Palen K, Dwinell MB, Johnson BD, Mackinnon A, Hessner MJ, Gershan JA) Cancer Epidemiol Biomarkers Prev 2018 Dec 07 PMID: 30530849 12/12/2018    
  • Frontline Science: PECAM-1 (CD31) expression in naïve and memory, but not acutely activated, CD8 T cells. (Newman DK, Fu G, McOlash L, Schauder D, Newman PJ, Cui W, Rao S, Johnson BD, Gershan JA, Riese MJ) J Leukoc Biol 2018 Nov;104(5):883-893 PMID: 30063264 PMCID: PMC6195461 08/01/2018       2 Citations
  • Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance. (Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ) Immunohorizons 2018 Apr 01;2(4):107-118 PMID: 30027154 PMCID: PMC6048965 07/22/2018    
  • Bone Marrow-derived CD8+ T Cells From Pediatric Leukemia Patients Express PD1 and Expand Ex Vivo Following Induction Chemotherapy. (Palen K, Thakar M, Johnson BD, Gershan JA) J Pediatr Hematol Oncol 2018 Jun 14 PMID: 29912035 06/19/2018    
  • T Cells Deficient in Diacylglycerol Kinase ζ Are Resistant to PD-1 Inhibition and Help Create Persistent Host Immunity to Leukemia. (Jing W, Gershan JA, Holzhauer S, Weber J, Palen K, McOlash L, Pulakanti K, Wesley E, Rao S, Johnson BD, Riese MJ) Cancer Res 2017 10 15;77(20):5676-5686 PMID: 28916658 09/17/2017    
  • Adoptive cell therapy using PD-1 myeloma-reactive T cells eliminates established myeloma in mice. (Jing W, Gershan JA, Blitzer GC, Palen K, Weber J, McOlash L, Riese M, Johnson BD) J Immunother Cancer 2017;5:51 PMID: 28642819 PMCID: PMC5477110 06/24/2017       2 Citations
  • Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer. (Riese MJ, Moon EK, Johnson BD, Albelda SM) Front Cell Dev Biol 2016;4:108 PMID: 27800476 PMCID: PMC5065962 11/02/2016    
  • E-cadherin re-expression shows in vivo evidence for mesenchymal to epithelial transition in clonal metastatic breast tumor cells. (Palen K, Weber J, Dwinell MB, Johnson BD, Ramchandran R, Gershan JA) Oncotarget 2016 Jul 12;7(28):43363-43375 PMID: 27270319 PMCID: PMC5190029 06/09/2016       7 Citations
  • Mitochondria-Targeted Analogues of Metformin Exhibit Enhanced Antiproliferative and Radiosensitizing Effects in Pancreatic Cancer Cells. (Cheng G, Zielonka J, Ouari O, Lopez M, McAllister D, Boyle K, Barrios CS, Weber JJ, Johnson BD, Hardy M, Dwinell MB, Kalyanaraman B) Cancer Res 2016 07 01;76(13):3904-15 PMID: 27216187 PMCID: PMC4930686 05/25/2016       43 Citations
  • Erratum to: Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. (Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA) Cancer Microenviron 2016 Apr;9(1):75 PMID: 26747049 PMCID: PMC4842184 01/10/2016    
  • p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion. (Qi X, Yin N, Ma S, Lepp A, Tang J, Jing W, Johnson B, Dwinell MB, Chitambar CR, Chen G) Stem Cells 2015 Sep;33(9):2738-47 PMID: 26077647 PMCID: PMC4792188 06/17/2015       11 Citations
  • Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma. (Jing W, Gershan JA, Weber J, Tlomak D, McOlash L, Sabatos-Peyton C, Johnson BD) J Immunother Cancer 2015;3(1):2 PMID: 25614821 PMCID: PMC4302511 01/24/2015    
  • Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma. (Kearl TJ, Jing W, Gershan JA, Johnson BD) J Immunol 2013 Jun 01;190(11):5620-8 PMID: 23616570 PMCID: PMC3891840 04/26/2013       56 Citations
  • Endothelial and Accessory Cell Interactions in Neuroblastoma Tumor Microenvironment (Chapter Title) (Jill Gershan, Andrew Chan, Magdalena Chrzanowska-Wodnicka, Bryon Johnson, Qing Robert Miao and Ramani Ramchandran) Research Directions in Tumor Angiogenesis (Book Title) ISBN: 978-953-51-0963-1 02/06/2013    
  • Macrophage migration inhibitory factor in head and neck squamous cell carcinoma: clinical and experimental studies. (Kindt N, Preillon J, Kaltner H, Gabius HJ, Chevalier D, Rodriguez A, Johnson BD, Megalizzi V, Decaestecker C, Laurent G, Saussez S) J Cancer Res Clin Oncol 2013 May;139(5):727-37 PMID: 23354841 01/29/2013       15 Citations
  • Examining T cells at vaccine sites of tumor-bearing hosts provides insights to dysfunctional T-cell immunity. (Barr KM, Jing W, Hallett WH, Gershan JA, Johnson BD) J Immunother 2013 Jan;36(1):41-51 PMID: 23211619 PMCID: PMC3521867 12/06/2012       1 Citations
  • HMGB1 release by urothelial carcinoma cells is required for the in vivo antitumor response to Bacillus Calmette-Guérin. (Zhang G, Chen F, Cao Y, Johnson B, See WA) J Urol 2013 Apr;189(4):1541-6 PMID: 23041342 10/09/2012       6 Citations
  • Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo. (Yan X, Doffek K, Yin C, Krein M, Phillips M, Sugg SL, Johnson B, Shilyansky J) Cancer Immunol Immunother 2012 Nov;61(11):1917-27 PMID: 22476407 04/06/2012       7 Citations
  • Exciting new murine model of cGVHD. (Johnson BD) Blood 2012 Feb 09;119(6):1331-2 PMID: 22323409 02/11/2012    
  • Separation and Characterization of Epithelial and Mesenchymal-like Murine Mammary Tumor Cells Reveals Epithelial Cell Differentiation Plasticity and Enhanced Tumorigenicity of Epithelial-enriched Tumor Cells. (Palen KA, Jing W, Weber JJ, Tilkens SB, Chan AM, Johnson BD, Gershan JA) Cancer Microenviron 2013 Apr;6(1):79-89 PMID: 22237886 PMCID: PMC3601216 01/13/2012    
  • Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade. (Hallett WH, Jing W, Drobyski WR, Johnson BD) Biol Blood Marrow Transplant 2011 Aug;17(8):1133-45 PMID: 21536144 05/04/2011       80 Citations
  • Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma. (Jing W, Yan X, Hallett WH, Gershan JA, Johnson BD) Blood 2011 Jun 23;117(25):6952-62 PMID: 21521781 PMCID: PMC3128485 04/28/2011       30 Citations
  • Increased expression of macrophage migration inhibitory factor during progression to hypopharyngeal squamous cell carcinoma. (Cludts S, Decaestecker C, Johnson B, Lechien J, Leroy X, Kindt N, Kaltner H, André S, Gabius HJ, Saussez S) Anticancer Res 2010 Sep;30(9):3313-9 PMID: 20944103 10/15/2010       14 Citations
  • Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data. (Kohler ME, Johnson BD, Palen K, Chen QR, Khan J, Orentas RJ) Cancer Sci 2010 Nov;101(11):2316-24 PMID: 20718755 PMCID: PMC3103783 08/20/2010       6 Citations
  • Early expression of stem cell-associated genes within the CD8 compartment after treatment with a tumor vaccine. (Kohler ME, Hallett WH, Chen QR, Khan J, Johnson BD, Orentas RJ) Cell Immunol 2010;265(1):65-73 PMID: 20692654 PMCID: PMC2935508 08/10/2010       4 Citations
  • Robert Truitt tribute. (Johnson B, Drobyski W, Blazar B, Korngold R) Biol Blood Marrow Transplant 2010 Jan;16(1):143-4 PMID: 19836456 10/20/2009    
  • Depletion of CD4 T cells enhances immunotherapy for neuroblastoma after syngeneic HSCT but compromises development of antitumor immune memory. (Jing W, Gershan JA, Johnson BD) Blood 2009 Apr 30;113(18):4449-57 PMID: 19182203 PMCID: PMC2676098 02/03/2009    
  • Induction of a VLA-2 (CD49b)-expressing effector T cell population by a cell-based neuroblastoma vaccine expressing CD137L. (Yan X, Johnson BD, Orentas RJ) J Immunol 2008 Oct 01;181(7):4621-31 PMID: 18802064 PMCID: PMC2975591 09/20/2008       12 Citations
  • Expression of macrophage migration inhibitory factor by neuroblastoma leads to the inhibition of antitumor T cell reactivity in vivo. (Zhou Q, Yan X, Gershan J, Orentas RJ, Johnson BD) J Immunol 2008 Aug 01;181(3):1877-86 PMID: 18641325 PMCID: PMC3804024 07/22/2008       26 Citations
  • Absence of regulatory T-cell control of TH1 and TH17 cells is responsible for the autoimmune-mediated pathology in chronic graft-versus-host disease. (Chen X, Vodanovic-Jankovic S, Johnson B, Keller M, Komorowski R, Drobyski WR) Blood 2007 Nov 15;110(10):3804-13 PMID: 17693581 PMCID: PMC2077325 08/19/2007       161 Citations
  • Cellular immune response to an engineered cell-based tumor vaccine at the vaccination site. (Zhou Q, Johnson BD, Orentas RJ) Cell Immunol 2007 Feb;245(2):91-102 PMID: 17543914 PMCID: PMC1949498 06/05/2007       4 Citations
  • CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. (Johnson BD, Jing W, Orentas RJ) J Immunother 2007 Feb-Mar;30(2):203-14 PMID: 17471167 05/02/2007       44 Citations
  • Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. (Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A) Cytotherapy 2007;9(2):144-57 PMID: 17453966 04/25/2007       36 Citations
  • Serum from mice immunized in the context of Treg inhibition identifies DEK as a neuroblastoma tumor antigen. (Zheng J, Kohler ME, Chen Q, Weber J, Khan J, Johnson BD, Orentas RJ) BMC Immunol 2007 Mar 30;8:4 PMID: 17397536 PMCID: PMC1852119 04/03/2007       9 Citations
  • Induction of immunity to neuroblastoma early after syngeneic hematopoietic stem cell transplantation using a novel mouse tumor vaccine. (Jing W, Orentas RJ, Johnson BD) Biol Blood Marrow Transplant 2007 Mar;13(3):277-92 PMID: 17317581 PMCID: PMC1852542 02/24/2007       19 Citations
  • Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. (Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR) J Thromb Haemost 2007 Feb;5(2):352-61 PMID: 17269937 02/03/2007       81 Citations
  • Immune response modulation by curcumin in a latex allergy model. (Kurup VP, Barrios CS, Raju R, Johnson BD, Levy MB, Fink JN) Clin Mol Allergy 2007 Jan 25;5:1 PMID: 17254346 PMCID: PMC1796894 01/27/2007    
  • Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. (Xia G, Truitt RL, Johnson BD) Biol Blood Marrow Transplant 2006 Apr;12(4):397-407 PMID: 16545723 03/21/2006       49 Citations
  • Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation. (Yan X, Orentas RJ, Johnson BD) Cytokine 2006 Feb 21;33(4):188-98 PMID: 16522371 PMCID: PMC2018658 03/09/2006       25 Citations
  • Suppression of anti-cancer immunity by regulatory T cells: back to the future. (Orentas RJ, Kohler ME, Johnson BD) Semin Cancer Biol 2006 Apr;16(2):137-49 PMID: 16376101 12/27/2005       55 Citations
  • The costimulatory molecules CD80, CD86 and OX40L are up-regulated in Aspergillus fumigatus sensitized mice. (Barrios CS, Johnson BD, D Henderson J Jr, Fink JN, Kelly KJ, Kurup VP) Clin Exp Immunol 2005 Nov;142(2):242-50 PMID: 16232210 PMCID: PMC1809515 10/20/2005       10 Citations
  • Neuroblastoma cells transiently transfected to simultaneously express the co-stimulatory molecules CD54, CD80, CD86, and CD137L generate antitumor immunity in mice. (Johnson BD, Gershan JA, Natalia N, Zujewski H, Weber JJ, Yan X, Orentas RJ) J Immunother 2005 Sep-Oct;28(5):449-60 PMID: 16113601 08/23/2005       28 Citations
  • Therapeutic expression of the platelet-specific integrin, alphaIIbbeta3, in a murine model for Glanzmann thrombasthenia. (Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC 2nd, Wilcox DA) Blood 2005 Oct 15;106(8):2671-9 PMID: 15972454 PMCID: PMC1895311 06/24/2005       54 Citations
  • Immediate transfection of patient-derived leukemia: a novel source for generating cell-based vaccines. (Gershan JA, Johnson BD, Weber J, Schauer DW, Natalia N, Behnke S, Burns K, Maloney KW, Warwick AB, Orentas RJ) Genet Vaccines Ther 2005 Jun 21;3(1):4 PMID: 15969754 PMCID: PMC1182385 06/23/2005    
  • Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host disease. (Xia G, Kovochich M, Truitt RL, Johnson BD) Biol Blood Marrow Transplant 2004 Nov;10(11):748-60 PMID: 15505606 10/27/2004       24 Citations
  • The T cell activation marker CD150 can be used to identify alloantigen-activated CD4(+)25+ regulatory T cells. (Browning MB, Woodliff JE, Konkol MC, Pati NT, Ghosh S, Truitt RL, Johnson BD) Cell Immunol 2004 Feb;227(2):129-39 PMID: 15135295 05/12/2004       16 Citations
  • Murine CD8 lymphocyte expansion in vitro by artificial antigen-presenting cells expressing CD137L (4-1BBL) is superior to CD28, and CD137L expressed on neuroblastoma expands CD8 tumour-reactive effector cells in vivo. (Yan X, Johnson BD, Orentas RJ) Immunology 2004 May;112(1):105-16 PMID: 15096190 PMCID: PMC1782467 04/21/2004       27 Citations
  • Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. (Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR) J Thromb Haemost 2003 Dec;1(12):2477-89 PMID: 14675082 12/17/2003       45 Citations
  • CD200 is a novel p53-target gene involved in apoptosis-associated immune tolerance. (Rosenblum MD, Olasz E, Woodliff JE, Johnson BD, Konkol MC, Gerber KA, Orentas RJ, Sandford G, Truitt RL) Blood 2004 Apr 01;103(7):2691-8 PMID: 14644999 12/03/2003       57 Citations
  • Dual expression of CD80 and CD86 produces a tumor vaccine superior to single expression of either molecule. (Johnson BD, Yan X, Schauer DW, Orentas RJ) Cell Immunol 2003 Mar;222(1):15-26 PMID: 12798304 06/12/2003       23 Citations
  • Photochemical treatment of donor lymphocytes inhibited their ability to facilitate donor engraftment or increase donor chimerism after nonmyeloablative conditioning or establishment of mixed chimerism. (Johnson BD, Taylor PA, Stankowski MC, Talib S, Hearst JE, Blazar BR) Biol Blood Marrow Transplant 2002;8(11):581-7 PMID: 12463476 12/05/2002    
  • CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. (Johnson BD, Konkol MC, Truitt RL) Biol Blood Marrow Transplant 2002;8(10):525-35 PMID: 12434947 11/19/2002       76 Citations
  • Production of macrophage migration inhibitory factor by human and murine neuroblastoma. (Bin Q, Johnson BD, Schauer DW, Casper JT, Orentas RJ) Tumour Biol 2002 May-Jun;23(3):123-9 PMID: 12218292 09/10/2002       15 Citations
  • Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. (Johnson BD, Dagher N, Stankowski WC, Hanke CA, Truitt RL) Biol Blood Marrow Transplant 2001;7(11):589-95 PMID: 11760146 01/05/2002       11 Citations
  • Electrofusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. (Orentas RJ, Schauer D, Bin Q, Johnson BD) Cell Immunol 2001 Oct 10;213(1):4-13 PMID: 11747351 12/19/2001       53 Citations
  • T cell proliferation and cytokine secretion to T cell epitopes of Asp f 2 in ABPA patients. (Rathore VB, Johnson B, Fink JN, Kelly KJ, Greenberger PA, Kurup VP) Clin Immunol 2001 Aug;100(2):228-35 PMID: 11465952 07/24/2001       22 Citations
  • Cloning and expression of Aspergillus fumigatus allergen Asp f 16 mediating both humoral and cell-mediated immunity in allergic bronchopulmonary aspergillosis (ABPA). (Banerjee B, Kurup VP, Greenberger PA, Johnson BD, Fink JN) Clin Exp Allergy 2001 May;31(5):761-70 PMID: 11422136 06/26/2001       44 Citations
  • Purified and recombinant latex proteins stimulate peripheral blood lymphocytes of latex allergic patients. (Johnson BD, Kurup VP, Sussman GL, Arif SA, Kelly KJ, Beezhold DH, Fink JN) Int Arch Allergy Immunol 1999 Dec;120(4):270-9 PMID: 10640910 01/21/2000       20 Citations
  • Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy. (Johnson BD, Becker EE, LaBelle JL, Truitt RL) J Immunol 1999 Dec 15;163(12):6479-87 PMID: 10586039 12/10/1999       61 Citations
  • Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. (Truitt RL, Johnson BD, Hanke C, Talib S, Hearst JE) J Immunol 1999 Nov 01;163(9):5145-56 PMID: 10528221 10/21/1999       45 Citations
  • Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. (Johnson BD, Becker EE, Truitt RL) Biol Blood Marrow Transplant 1999;5(3):123-32 PMID: 10392958 07/07/1999       51 Citations
  • Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro. (Johnson BD, Hanke CA, Becker EE, Truitt RL) Cell Immunol 1998 Nov 01;189(2):149-59 PMID: 9790729 10/29/1998       11 Citations
  • The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. (Johnson BD, Hanke CA, Truitt RL) Leuk Lymphoma 1996 Sep;23(1-2):1-9 PMID: 9021679 09/01/1996       12 Citations
  • Principles of graft-vs.-leukemia reactivity. (Truitt RL, Johnson BD) Biol Blood Marrow Transplant 1995 Dec;1(2):61-8 PMID: 9118293 12/01/1995       62 Citations
  • Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. (Johnson BD, Truitt RL) Blood 1995 Jun 01;85(11):3302-12 PMID: 7756664 06/01/1995       129 Citations
  • Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. (Johnson BD, McCabe C, Hanke CA, Truitt RL) J Immunol 1995 May 15;154(10):5542-54 PMID: 7730653 05/15/1995       40 Citations
  • Induction of porcine granulocyte-mediated tumor cytotoxicity by two distinct monoclonal antibodies against lytic trigger molecules (PNK-E/G7). (Wierda WG, Johnson BD, Dato ME, Kim YB) J Immunol 1993 Dec 15;151(12):7117-27 PMID: 8258715 12/15/1993       15 Citations
  • Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. (Johnson BD, Drobyski WR, Truitt RL) Bone Marrow Transplant 1993 Apr;11(4):329-36 PMID: 8485480 04/01/1993       122 Citations
  • Two distinct porcine natural killer lytic trigger molecules as PNK-E/G7 molecular complex. (Wierda WG, Johnson BD, Dato ME, Kim YB) Cell Immunol 1993 Feb;146(2):270-83 PMID: 8174170 02/01/1993       11 Citations
  • A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. (Johnson BD, Truitt RL) Transplantation 1992 Jul;54(1):104-12 PMID: 1631918 07/01/1992       48 Citations
  • Further characterization of PNK-E: a monoclonal antibody enhancing porcine natural killer cell activity. (Johnson BD, Wierda WG, Kim YB) Cell Immunol 1991 May;134(2):378-89 PMID: 2021974 05/01/1991       9 Citations
  • Characterization of a monoclonal antibody enhancing porcine natural killer cell activity (PNK-E). (Johnson BD, Kim YB) Cell Immunol 1990 Jan;125(1):107-19 PMID: 2293895 01/01/1990       11 Citations
  • C-reactive protein is involved in natural killer cell-mediated lysis but does not mediate effector-target cell recognition. (Baum LL, Johnson B, Berman S, Graham D, Mold C) Immunology 1987 May;61(1):93-9 PMID: 3583316 PMCID: PMC1453307 05/01/1987       15 Citations
  • Last update: 02/25/2019
    jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70